Endoscopic ultrasound-guided radiofrequency ablation of pancreatic tumors: Current status and future perspectives.

Pancreatic neoplasms present a significant therapeutic challenge due to their complex anatomy and poor prognosis. In recent years, endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) has emerged as a promising minimally invasive therapeutic option, aiming to provide targeted treatment with improved patients' outcomes. This review aims to shed light on current evidence about the efficacy, safety, and clinical outcomes of EUS-RFA in the management of pancreatic neoplasms. We conducted a comprehensive search of literature, reviewing studies that document the application of EUS-RFA in pancreatic masses. The key metrics for efficacy included tumor size reduction, pain relief, and overall survival, while safety outcomes focused on procedural complications and post-operative recovery. EUS-RFA has demonstrated potential in effectively managing both benign and malignant pancreatic neoplasms, with several studies reporting significant reductions in tumor size and symptomatic relief. The technique is associated with a favorable safety profile, characterized by a low incidence of major complications. EUS-RFA represents a valuable addition to the therapeutic arsenal for pancreatic neoplasms, offering a viable alternative to surgical interventions, especially in patients with contraindications for surgery. Further studies are needed to establish standardized protocols and long-term outcomes, enhancing its applicability and success in clinical practice.